TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY
Objective: to study the time course of changes in laboratory biomarkers in patients with rheumatoid arthritis (RA) 2, 4, and 8 weeks after the initiation of tocilizumab (TCZ) therapy. Subjects and methods. Forty-two RA patients receiving two intravenous infusions of TCZ (8 mg/kg each) at a 4-week in...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2011-06-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/705 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839568458719690752 |
|---|---|
| author | E N Aleksandrova E Yu Panasyuk A S Avdeyeva A A Novikov G V Lukina M V Cherkasova N V Klimova E L Nasonov |
| author_facet | E N Aleksandrova E Yu Panasyuk A S Avdeyeva A A Novikov G V Lukina M V Cherkasova N V Klimova E L Nasonov |
| author_sort | E N Aleksandrova |
| collection | DOAJ |
| description | Objective: to study the time course of changes in laboratory biomarkers in patients with rheumatoid arthritis (RA) 2, 4, and 8 weeks after the initiation of tocilizumab (TCZ) therapy. Subjects and methods. Forty-two RA patients receiving two intravenous infusions of TCZ (8 mg/kg each) at a 4-week interval during steady-state therapy with disease-modifying anti-inflammatory agents and glucocorticoids were examined. At week 8 of therapy, there were good and moderate effects in 21 and 20 patients, respectively, according to the EULAR criteria; no effect was found in 1 patient. Erythrocyte sedimentation rate (ESR) was determined by the Westergren method; the serum levels of C-reactive protein (CRP) and IgM rheumatoid factor (RF) were measured by the nephelometric method; anti-cyclic citrullinated peptide antibodies (ACCPA) were estimated by an ummunoluminescence assay. Serum interleukin (IL) 6 concentrations were measured by multiplex analysis; IgA RF, anti-modified citrullinated vimentin (anti-MCV) antibodies, and soluble IL-6 receptors (sIL-6R) were determined by enzyme immunoassay. Results. The patients who showed a response to TCZ therapy had the basal values: Me (RI 25-75 percentile) was 42 (30-70) mm/hr for ESR, 35.2 (19.2-62.7) mg/l for CRP, 263.0 (95.3-663.0) IU/ml for IgM RF, 347.0 (131.2-789.0) IU/ml for IgA RF, 378.8 (85.8-500.0) IU/ml for ACCPA, 778.6 (190.7-2393.1) IU/ml for anti-MCV, 182.2 (106.1-462.3) pg/ml for IL-6, and 267.2 (212.5-310.0) ng/ml for sIL-6R. At TCZ therapy week 2, there were reductions in ESR [12 (6-18) mm/hr], CRP [0.5(0.3-0.9) mg/l], IgM RF [174.0 (40.8-513.0) IU/ml], and IgA RF [227.2 (62.1-570.8) IU/ml]; at week 4, anti-MCV titers were 313.5 (79.9-960.3) IU/ml, which remained until week 8 (p < 0.01). IL-6 concentrations were increased at week 2 and reduced at week 8; these were 418.4 (287.0-678.3) and 103.4 (39.1-208.5) pg/ml, respectively (p < 0.01). The elevated sIL-6R level of 1250.0 (1250.0-1475.0) ng/ml was recorded at weeks 2 to 8 of TCZ use (p < 0.01). Conclusion. The interim analysis of the efficacy of two TCZ infusions 2, 4, and 8 weeks after the initiation of the therapy suggests that TCZ is able to induce steady-state positive changes in immune-inflammatory markers very rapidly in patients with RA |
| format | Article |
| id | doaj-art-aac0d9f19f0c4d74abf8e1e33e67bbfe |
| institution | Matheson Library |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2011-06-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-aac0d9f19f0c4d74abf8e1e33e67bbfe2025-08-04T17:03:52ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922011-06-01493141910.14412/1995-4484-2011-567645TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPYE N AleksandrovaE Yu PanasyukA S AvdeyevaA A NovikovG V LukinaM V CherkasovaN V KlimovaE L NasonovObjective: to study the time course of changes in laboratory biomarkers in patients with rheumatoid arthritis (RA) 2, 4, and 8 weeks after the initiation of tocilizumab (TCZ) therapy. Subjects and methods. Forty-two RA patients receiving two intravenous infusions of TCZ (8 mg/kg each) at a 4-week interval during steady-state therapy with disease-modifying anti-inflammatory agents and glucocorticoids were examined. At week 8 of therapy, there were good and moderate effects in 21 and 20 patients, respectively, according to the EULAR criteria; no effect was found in 1 patient. Erythrocyte sedimentation rate (ESR) was determined by the Westergren method; the serum levels of C-reactive protein (CRP) and IgM rheumatoid factor (RF) were measured by the nephelometric method; anti-cyclic citrullinated peptide antibodies (ACCPA) were estimated by an ummunoluminescence assay. Serum interleukin (IL) 6 concentrations were measured by multiplex analysis; IgA RF, anti-modified citrullinated vimentin (anti-MCV) antibodies, and soluble IL-6 receptors (sIL-6R) were determined by enzyme immunoassay. Results. The patients who showed a response to TCZ therapy had the basal values: Me (RI 25-75 percentile) was 42 (30-70) mm/hr for ESR, 35.2 (19.2-62.7) mg/l for CRP, 263.0 (95.3-663.0) IU/ml for IgM RF, 347.0 (131.2-789.0) IU/ml for IgA RF, 378.8 (85.8-500.0) IU/ml for ACCPA, 778.6 (190.7-2393.1) IU/ml for anti-MCV, 182.2 (106.1-462.3) pg/ml for IL-6, and 267.2 (212.5-310.0) ng/ml for sIL-6R. At TCZ therapy week 2, there were reductions in ESR [12 (6-18) mm/hr], CRP [0.5(0.3-0.9) mg/l], IgM RF [174.0 (40.8-513.0) IU/ml], and IgA RF [227.2 (62.1-570.8) IU/ml]; at week 4, anti-MCV titers were 313.5 (79.9-960.3) IU/ml, which remained until week 8 (p < 0.01). IL-6 concentrations were increased at week 2 and reduced at week 8; these were 418.4 (287.0-678.3) and 103.4 (39.1-208.5) pg/ml, respectively (p < 0.01). The elevated sIL-6R level of 1250.0 (1250.0-1475.0) ng/ml was recorded at weeks 2 to 8 of TCZ use (p < 0.01). Conclusion. The interim analysis of the efficacy of two TCZ infusions 2, 4, and 8 weeks after the initiation of the therapy suggests that TCZ is able to induce steady-state positive changes in immune-inflammatory markers very rapidly in patients with RAhttps://rsp.mediar-press.net/rsp/article/view/705rheumatoid arthritis, interleukin-6interleukin-6 receptorstocilizumab, erythrocyte sedimentation ratec-reactive protein, igm/iga rheumatoid factoranti-cyclic citrullinated peptide antibodiesanti-modified citrullinated vimentin antibodies |
| spellingShingle | E N Aleksandrova E Yu Panasyuk A S Avdeyeva A A Novikov G V Lukina M V Cherkasova N V Klimova E L Nasonov TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY Научно-практическая ревматология rheumatoid arthritis, interleukin-6 interleukin-6 receptors tocilizumab, erythrocyte sedimentation rate c-reactive protein, igm/iga rheumatoid factor anti-cyclic citrullinated peptide antibodies anti-modified citrullinated vimentin antibodies |
| title | TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY |
| title_full | TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY |
| title_fullStr | TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY |
| title_full_unstemmed | TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY |
| title_short | TIME COURSE OF CHANGES IN LABORATORY BIOMARKERS IN PATIENTS WITH RHEUMATOID ARTHRITIS DURING TOCILIZUMAB THERAPY |
| title_sort | time course of changes in laboratory biomarkers in patients with rheumatoid arthritis during tocilizumab therapy |
| topic | rheumatoid arthritis, interleukin-6 interleukin-6 receptors tocilizumab, erythrocyte sedimentation rate c-reactive protein, igm/iga rheumatoid factor anti-cyclic citrullinated peptide antibodies anti-modified citrullinated vimentin antibodies |
| url | https://rsp.mediar-press.net/rsp/article/view/705 |
| work_keys_str_mv | AT enaleksandrova timecourseofchangesinlaboratorybiomarkersinpatientswithrheumatoidarthritisduringtocilizumabtherapy AT eyupanasyuk timecourseofchangesinlaboratorybiomarkersinpatientswithrheumatoidarthritisduringtocilizumabtherapy AT asavdeyeva timecourseofchangesinlaboratorybiomarkersinpatientswithrheumatoidarthritisduringtocilizumabtherapy AT aanovikov timecourseofchangesinlaboratorybiomarkersinpatientswithrheumatoidarthritisduringtocilizumabtherapy AT gvlukina timecourseofchangesinlaboratorybiomarkersinpatientswithrheumatoidarthritisduringtocilizumabtherapy AT mvcherkasova timecourseofchangesinlaboratorybiomarkersinpatientswithrheumatoidarthritisduringtocilizumabtherapy AT nvklimova timecourseofchangesinlaboratorybiomarkersinpatientswithrheumatoidarthritisduringtocilizumabtherapy AT elnasonov timecourseofchangesinlaboratorybiomarkersinpatientswithrheumatoidarthritisduringtocilizumabtherapy |